Maria José Alves Rocha

Maria José Alves Rocha

Auto-generated profile, based on publicly available information

Maria José Alves Rocha

Department of Psychology, Faculty of Philosophy, Sciences and Letters at Ribeirão Preto, University of São Paulo, Ribeirão Preto-SP, Brazil

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
CCCarlos Henrique Rocha Catalão
Carlos Henrique Rocha Catalão
Anderson Oliveira SouzaAnderson Oliveira Souza
Anderson Oliveira Souza
NSNilton Nascimento Santos-Junior
Nilton Nascimento Santos-Junior
LCLuis Henrique Angenendt da Costa
Luis Henrique Angenendt da Costa
JSJonathas dos Santos
Jonathas dos Santos
MRMaria José Alves Rocha
Maria José Alves Rocha

7 November 2024 in Biochemical Journal
Verified
Journal Article
Open access
CCCarlos Henrique Rocha Catalão
Carlos Henrique Rocha Catalão
LCLuis Henrique Angenendt da Costa
Luis Henrique Angenendt da Costa
JSJonathas Rodrigo dos Santos
Jonathas Rodrigo dos Santos
LALuciane Carla Alberici
Luciane Carla Alberici
LFLuiz Luciano Falconi-Sobrinho
Luiz Luciano Falconi-Sobrinho
MRMaria José Alves Rocha
Maria José Alves Rocha
Existing literature suggests that infection-specific mechanisms may play a significant role in the onset and progression of dementia, as opposed to the broader phenomenon of systemic inflammation. In addition, 3-hydroxy-3-methylglutaryl (HMG)-coenzyme A (CoA) reductase inhibitors have been proposed as a potential therapeutic approach for sepsis, given their anti-inflammatory and antioxidant properties. We investigated the neuroprotective effect of an HMG-CoA reductase inhibitor (simvastatin) by analyzing neurodegenerative markers, mitochondrial respiration, and neuronal tracing in the prefrontal cortex (PFC) and thalamic nucleus reuniens (RE) of sepsis survivor animals. Adult Wistar rats were subjected to sepsis by cecal ligation and puncture or left non-manipulated. The animals were treated with simvastatin or vehicle for 4 days before and 10 days after surgery. The treatment preserved the non-associative memory (P < 0.05), recovered expression of Smad-3 in the hippocampus (P < 0.05), and prevented increased expression of calpain-1 (hippocampus: P < 0.0001; PFC: P < 0.05) and GSKβ (hippocampus: P < 0.0001; PFC: P < 0.0001) in the brain structures of the sepsis survivor animals. These animals also showed mitochondrial dysfunction and decreased axon terminals in the RE. Simvastatin seems to restore energy metabolism by improving the electron transfer system (ETS) values in the hippocampus (P < 0.01) and the oxidative phosphorylation/ETS (P/E) ratio in the PFC (P < 0.05), in addition to preventing the reduction of axon terminals in survivor animals. These results suggest a potential neuroprotective effect and the importance of considering HMG-CoA reductase inhibitors as a possible adjuvant therapy in sepsis.

21 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
CCCarlos Henrique Rocha Catalão
Carlos Henrique Rocha Catalão
Anderson Oliveira SouzaAnderson Oliveira Souza
Anderson Oliveira Souza
NSNilton Nascimento Santos-Junior
Nilton Nascimento Santos-Junior
LCLuis Henrique Angenendt da Costa
Luis Henrique Angenendt da Costa
JSJonathas dos Santos
Jonathas dos Santos
MRMaria José Alves Rocha
Maria José Alves Rocha
Sepsis causes overproduction of inflammatory cytokines, organ dysfunction and cognitive impairment in survivors. In addition to inflammation, metabolic changes occur according to the stage and severity of the disease. Understanding the role and place of metabolic disturbances in the pathophysiology of sepsis is essential to evaluate the framework of septic patients, predict the syndrome progress and define treatment strategies. We investigated the effect of simvastatin on the disease time course and on metabolic alterations, especially with respect to their possible consequences in the CNS of surviving rats. The animals of this study were weighed daily and followed for 10 days to determine the survival rate. In the first experiment, control or CLP-animals were randomized in 24 h, 48 h and 10 days after septic induction, for bacterial load determination and, quantification of cytokines. In the second experiment, control or CLP-animals were treated or not with simvastatin and randomized in the same three time points for cytokines quantification and assessment of their body metabolism and locomotor activity (at 48 h and 10 days), as well as the evaluation of cytoarchitecture and astrogliosis (at 10 days). The CLP-rats treated with simvastatin showed a reduction in plasma cytokines and improvement in metabolic parameters and locomotor activity, followed by minor alterations compatible with apoptosis and astrogliosis in the hippocampus and prefrontal cortex. These results suggest that the anti-inflammatory effect of simvastatin plays a crucial role in restoring energy production, maintaining a hypermetabolic state necessary for the recovery and survival of these CLP-rats.